Evonetix Ltd

Evonetix Ltd is a Cambridge-based startup founded in 2015, with a mission to revolutionize the field of gene synthesis. The company's slogan, "Technology to ignite the biology revolution," encapsulates its ambitious goal. Evonetix is focused on developing a novel approach to gene synthesis through its desktop DNA synthesis platform. This technology promises to enable the synthesis of DNA with unprecedented accuracy, scale, and speed, thus empowering scientists to leverage synthetic biology on a scale that is currently unattainable. The recent Series B investment of £20.00M on February 7, 2023, marked a significant milestone for Evonetix. The impressive roster of investors participating in this round includes Civilization Ventures, DCVC, Molten Ventures, Cambridge Consultants, Foresite Capital, Page One Ventures, Providence Investment Company Limited, and Morningside Group. This level of backing underscores the confidence that leading venture capital firms have in Evonetix's innovative approach and its potential to disrupt the biopharma, biotechnology, and life sciences sectors. With its headquarters in the United Kingdom, Evonetix is well-positioned to be a key player in the global biotech landscape.